{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T03:41:50Z","timestamp":1783222910063,"version":"3.54.6"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T00:00:00Z","timestamp":1559692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin in patients with chronic heart failure and type II diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty-five Japanese patients with chronic heart failure and type II diabetes were treated with canagliflozin for 12\u00a0months. The primary endpoints were the changes of subcutaneous, visceral, and total fat areas at 12\u00a0months determined by computed tomography. Secondary endpoints included markers of glycemic control, renal function, and oxidative stress, as well as lipid parameters, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), flow-mediated dilation (FMD), and echocardiographic left ventricular function.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All fat areas (subcutaneous, visceral, and total) showed a significant decrease at 12\u00a0months. ANP and BNP also decreased significantly, along with improvement of renal function, oxidized LDL, and E\/e\u2032, FMD increased significantly after canagliflozin treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Canagliflozin demonstrated cardiac and renal protective effects as well as improving oxidative stress, diastolic function, and endothelial function. This drug was effective in patients who had heart failure with preserved ejection fraction and could become first-line therapy for such patients with diabetes.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> UMIN (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.umin.ac.jp\/\">http:\/\/www.umin.ac.jp\/<\/jats:ext-link>), Study ID: UMIN000021239<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-019-0877-2","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T12:02:48Z","timestamp":1559736168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Canagliflozin for Japanese patients with chronic heart failure and type II diabetes"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"umin000021239","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3474-9082","authenticated-orcid":false,"given":"Akira","family":"Sezai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakuni","family":"Sekino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Unosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Taoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Osaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,5]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"877_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"877_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812389","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/nejmoa1812389.","journal-title":"N Engl J Med"},{"key":"877_CR4","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/ejhf.933","volume":"19","author":"J Butler","year":"2017","unstructured":"Butler J, Hamo CR, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, et al. The potential role and rationale for treatment of heart failure with sodium\u2013glucose cotransporter 2 inhibitors. Eur J Heart Fail. 2017;19:1390\u2013400.","journal-title":"Eur J Heart Fail"},{"key":"877_CR5","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","volume":"89","author":"H Rajasekeran","year":"2016","unstructured":"Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium\u2013glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 2016;89:524\u20136.","journal-title":"Kidney Int"},{"key":"877_CR6","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1253\/circj.CJ-18-0584","volume":"82","author":"T Okumura","year":"2018","unstructured":"Okumura T, Murohara T. Are sodium\u2013glucose cotransporter 2 inhibitors really useful and safe for advanced heart failure? Circ J. 2018;82:1752\u20133.","journal-title":"Circ J"},{"key":"877_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1253\/circj.CJ-16-1304","volume":"81","author":"YK Bando","year":"2017","unstructured":"Bando YK, Murohara T. Asian perspective of the EMPA-REG OUTCOME study. Circ J. 2017;81:155\u20137.","journal-title":"Circ J"},{"key":"877_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1507\/endocrj.EJ15-0749","volume":"63","author":"C Yamamoto","year":"2016","unstructured":"Yamamoto C, Miyoshi H, Ono K, Sugawara H, Kameda R, Ichiyama M, et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. Endocr J. 2016;63:589\u201396.","journal-title":"Endocr J"},{"key":"877_CR9","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941\u201350.","journal-title":"Lancet"},{"key":"877_CR10","doi-asserted-by":"publisher","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","volume":"9","author":"N Terami","year":"2014","unstructured":"Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka S, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS ONE. 2014;9:e100777.","journal-title":"PLoS ONE"},{"key":"877_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12933-018-0773-1","volume":"17","author":"S Ida","year":"2018","unstructured":"Ida S, Kaneko R, Murata K. Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis. Cardiovasc Diabetol. 2018;17:129.","journal-title":"Cardiovasc Diabetol"},{"key":"877_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12933-017-0564-0","volume":"16","author":"F Shigiyama","year":"2017","unstructured":"Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc Diabetol. 2017;16:84.","journal-title":"Cardiovasc Diabetol"},{"key":"877_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fcvm.2016.00043","volume":"3","author":"HM Salim","year":"2016","unstructured":"Salim HM, Fukuda D, Yagi S, Soeki T, Shimabukuro M, Sata M. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front Cardiovasc Med. 2016;3:43.","journal-title":"Front Cardiovasc Med"},{"key":"877_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334.","journal-title":"N Engl J Med"},{"key":"877_CR15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6:691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"877_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17:73.","journal-title":"Cardiovasc Diabetol"},{"key":"877_CR17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12933-018-0775-z","volume":"17","author":"F Soga","year":"2018","unstructured":"Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17:132.","journal-title":"Cardiovasc Diabetol"},{"key":"877_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12933-016-0419-0","volume":"15","author":"JS Singh","year":"2016","unstructured":"Singh JS, Fathi A, Vickneson K, Mordi I, Mohan M, Houston JG, et al. Research into the effect of SGLT2 inhibition on left ventricular remodeling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016;15:97.","journal-title":"Cardiovasc Diabetol"},{"key":"877_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12872-017-0663-6","volume":"17","author":"AJM Brown","year":"2017","unstructured":"Brown AJM, Lang C, McCrimmon R, Struthers A. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study. BMC Cardiovasc Disord. 2017;17:229.","journal-title":"BMC Cardiovasc Disord"},{"key":"877_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-017-0615-6","volume":"16","author":"A Natali","year":"2017","unstructured":"Natali A, Nesti L, Fabiani I, Calogero E, Di Bello V. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Diabetol. 2017;16:130.","journal-title":"Cardiovasc Diabetol"},{"key":"877_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","volume":"9","author":"S Yagi","year":"2017","unstructured":"Yagi S, Hirata Y, Ise T, Kusunose K, Yamada H, Fukuda D, et al. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2017;9:78.","journal-title":"Diabetol Metab Syndr"},{"key":"877_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","volume":"16","author":"R Bouchi","year":"2017","unstructured":"Bouchi R, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, et al. Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabetol. 2017;16:32.","journal-title":"Cardiovasc Diabetol"},{"key":"877_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther. 2017;31:233\u201346.","journal-title":"Cardiovasc Drugs Ther"},{"key":"877_CR24","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kov\u00e1cs \u00c1, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20:1690\u2013700.","journal-title":"Eur J Heart Fail"},{"key":"877_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.119.040130","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019. https:\/\/doi.org\/10.1161\/circulationaha.119.040130.","journal-title":"Circulation"},{"key":"877_CR26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1507\/endocrj.EJ18-0022","volume":"65","author":"T Ninomiya","year":"2018","unstructured":"Ninomiya T, Shimono D, Horikawa T, Fujimura Y, Ohsako T, Terawaki Y, et al. Efficacy and safety of sodium\u2013glucose cotransporter 2 inhibitor ipragliozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragli ozin (FUSION). Endocr J. 2018;65:859\u201367.","journal-title":"Endocr J"},{"key":"877_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s12325-016-0457-8","volume":"34","author":"H Tanaka","year":"2017","unstructured":"Tanaka H, Takano K, Iijima H, Kubo H, Maruyama N, Hashimoto T, et al. Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv Ther. 2017;34:436\u201351.","journal-title":"Adv Ther"},{"key":"877_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/ijms20030629","volume":"20","author":"TM Ansary","year":"2019","unstructured":"Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019;20:629.","journal-title":"Int J Mol Sci"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0877-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-019-0877-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0877-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:12:40Z","timestamp":1628611960000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0877-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0877-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,5]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Sekino Hospital Review Board. All study participants consented to participating in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants provided written informed consent before enrollment in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}